Replies to post #292826 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

I am guessing that the IDH mutation work was the main reason for the post April 18 delay and that NWBO would not have delayed DL and TLD by more than 3 months if they did not consider the IDH mutation data to be very important.

That might be.

But why would a quasi post hoc subgroup be that important? If the ITT population shows a clear benefit, game over.

Also, why the MRIs?

A hell of a lot happened in this trial. It has gone on and on. NWBO has often never been on the best terms with creditors, and that could include the CROs. And if the data was never even collected from the 80+ hospitals as the trial went on, how could you even be certain the hospitals would keep all the needed data?